Working with TipRanks
Follow Us
Stock Ideas
Daily Updates
Calendars
Education
About Us
Working with TipRanks
Follow Us
Inozyme Pharma (INZY)
NASDAQ:INZY
Inozyme Pharma (INZY) Stock Price & Analysis
171 Followers
INZY Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.99 - $7.24
Previous Close$6.43
Volume567.96K
Average Volume (3M)753.21K
Market Cap
$283.15M
Enterprise Value$178.88M
Total Cash (Recent Filing)$130.93M
Total Debt (Recent Filing)$26.66M
Price to Earnings (P/E)-4.0
Beta0.65
Next Earnings
Sep 07, 2023EPS Estimate
-$0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.62
Shares Outstanding44,035,322
10 Day Avg. Volume466,934
30 Day Avg. Volume753,208
Standard Deviation0.34
R-Squared0.03
Alpha-0.00401
Financial Highlights & Ratios
Price to Book (P/B)2.68
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-2.54
Forecast
1Y Price Target
$19.67Price Target Upside205.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Inozyme Pharma News
Pre-EarningsINZY Earnings this Week: How Will it Perform?
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Insights
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
INZY FAQ
What was Inozyme Pharma’s price range in the past 12 months?
Inozyme Pharma lowest stock price was $0.99 and its highest was $7.24 in the past 12 months.
What is Inozyme Pharma’s market cap?
Currently, no data Available
When is Inozyme Pharma’s upcoming earnings report date?
Inozyme Pharma’s upcoming earnings report date is Sep 07, 2023 which is in 96 days.
How were Inozyme Pharma’s earnings last quarter?
Inozyme Pharma released its earnings results on May 09, 2023. The company reported -$0.4 earnings per share for the quarter, beating the consensus estimate of -$0.446 by $0.046.
Is Inozyme Pharma overvalued?
According to Wall Street analysts Inozyme Pharma’s price is currently Undervalued.
Does Inozyme Pharma pay dividends?
Inozyme Pharma does not currently pay dividends.
What is Inozyme Pharma’s EPS estimate?
Inozyme Pharma’s EPS estimate is -$0.44.
How many shares outstanding does Inozyme Pharma have?
Inozyme Pharma has 44,035,320 shares outstanding.
What happened to Inozyme Pharma’s price movement after its last earnings report?
Inozyme Pharma reported an EPS of -$0.4 in its last earnings report, beating expectations of -$0.446. Following the earnings report the stock price went up 9.532%.
Which hedge fund is a major shareholder of Inozyme Pharma?
Among the largest hedge funds holding Inozyme Pharma’s share is Deerfield Management Company, LP. It holds Inozyme Pharma’s shares valued at N/A.
---
Inozyme Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.67 (205.91% Upside)
$19.67 (205.91% Upside)
Blogger Sentiment
Bullish
INZY Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 2.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $5.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 3.7%
Last 30 Days ▲ 3.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
100.93%
12-Months-Change
Fundamentals
Return on Equity
-68.41%
Trailing 12-Months
Asset Growth
30.17%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Inozyme Pharma
Inozyme Pharma Inc is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies.
---
Top 5 ETFs holding INZY
Vanguard Total Stock Market ETF
$4.64M
Up to five ETFs with an Outperform Smart Score that hold INZY. The ETFs are listed according to market value of INZY within the ETF
---
Regulus
―
Bioxcel Therapeutics
―
Crinetics Pharmaceuticals
―
Adaptimmune Therapeutics
―
---